Ensysce 8-K/A No. 2 Details Cy Biopharma Deal: Going-Concern Target, $79M IPR&D Write-Off, Nasdaq Listing Risk

summarizeSummary

Ensysce's Amendment No. 2 to its August 2026 8-K supplies Cy Biopharma's financials, pro forma statements and risk factors, disclosing a going-concern paragraph on the acquired company, a $79.2 million one-time IPR&D write-off, and Nasdaq listing risk tied to the Series C conversion.

check_boxKey Events · M&A and Partnerships · ENSC

• Cy Biopharma Financials Show Going Concern

  Cy Biopharma's audited December 31, 2025 statements carry a going-concern explanatory paragraph, with an accumulated deficit of $3,922,982 and a working capital deficit of $308,532; the June 30, 2026 interim statements repeat substantial doubt.

• $79.2M IPR&D Charge Hits Pro Forma Earnings

  The pro forma FY2025 statement of operations reflects immediate expensing of approximately $79.2 million of acquired CY200 in-process research and development with no alternative future use, driving a pro forma net loss of $91.6 million.

• Pro Forma Cash of $39.4M After Closings

  Pro forma cash combines the $21.5 million initial PIPE tranche, $11.4 million of July 2026 Cy convertible note proceeds and existing balances, totaling $39,406,895; the second $21.5 million PIPE tranche and $8.9 million Cy holder tranche remain contingent on an unachieved Phase 2 milestone.

• Series C Conversion Would Add 358.3M Shares

  Risk factors state that conversion of the Series C Preferred Stock would issue an additional 358,292,000 common shares, with 75,615,000 more issuable upon the milestone, and that insiders would hold approximately 41.2% of the post-conversion common stock.

auto_awesomeAnalysis · ENSC · Life Sciences

This Amendment No. 2 supplies the financial statements, pro forma information and risk factors that were missing from the August 6, 2026 8-K and 8-K/A covering the Cy Biopharma acquisition. Two items stand out. First, Cy Biopharma's own audited financials carry a going-concern explanatory paragraph — accumulated deficit of $3.9 million and a working capital deficit of $0.3 million at December 31, 2025 — meaning Ensysce acquired a company that could not fund itself, which is why the combined entity now depends on the PIPE tranches and the $17.1 million Cy convertible note financing. Second, the pro forma statements show a $79.2 million immediate expensing of acquired CY200 in-process research and development with no alternative future use, producing a pro forma FY2025 net loss of $91.6 million; that charge is non-cash and one-time, but it wipes out reported earnings optics for the combined company. The risk factors also quantify the dilution: conversion of the Series C Preferred Stock would add 358,292,000 common shares, with another 75,615,000 issuable if the clinical milestone is met, and they disclose that Nasdaq has ruled the transaction a change of control requiring a full initial listing application with a $4.00 minimum bid price before stockholders can approve the conversion. The second $21.5 million PIPE tranche and the $8.9 million Cy holder tranche are contingent on a Phase 2 CY200 milestone that has not been achieved, so the company would need alternative financing if it slips. Pro forma cash after the initial closing and the July 2026 note proceeds is $39.4 million, which funds the CY200 Phase 2 trial toward topline data but does not remove the going-concern and listing overhangs.